Berkeley Architect sustains his vision despite blindness

Oh, that we could see as clearly as blind architect Chris Downey. Leading his UC Berkeley seminar students to equitable, barrier-eliminating design solutions or consulting on a 170,000-square-foot blind rehab center at the Veterans Affairs center in Palo Alto or filling the stroke seat on his East Bay Rowing Club team, the 52-year-old Piedmont architect and teacher says he lacks sight, but is not without vision.

Tablet computers for the blind in development

Is Braille on the way out? Do we have enough interest in teaching Braille to visually impaired students? Considering some of the subject matter cannot be explained to them by voice, are there any attempts to make this means of communication more accessible via smartphones and technology in the current age? Surprising to some, there are attempts being made to develop this technology to help the visually impaired students.

Intas launches RAZUMAB, the first biosimilar to Lucentis (ranibizumab)

Intas Pharmaceuticals has launched RAZUMAB, its biosimilar to Lucentis (ranibizumab).

Converting rods into cones in a model of retinitis pigmentosa (RP) rescues retinal degeneration

Heritable retinal degeneration is a common cause of visual impairment and blindness, affecting millions of people worldwide. Many research groups have focused on targeted gene therapy as a treatment for these diseases. However, inherited retinal diseases can be caused by mutations in any one of more than 200 genes, and the pathogenic mechanisms of various mutations differ greatly. This was the motivating factor in the work by Dr James C Corbo and his team at the Washington University School of Medicine to develop gene-independent therapies that would be more widely applicable. This work has been published in the Proceedings of the National Academy of Sciences.

Study challenges conventional wisdom that sight-based brain sensory network is impaired with blindness

Is visual input essential to how the topographical map of the visual cortex develops in the human brain? In a new research, scientists at the Hebrew University of Jerusalem, and those from in Germany and USA, show that the way in which the brain organizes its visual sense remains intact even in people who are blind from birth.

New development in the race to bring bionic eye closer to patients

A French company called Pixium Vision is testing a system called Iris that promises to improve the vision of the blind.

A major advance in gene therapy for Retinitis Pigmentosa

A paper published in Nature Communications sheds light on why, until now, it has not been possible to effectively restore vision in rd1 mice – the world’s major model for retinitis pigmentosa (RP). This research also demonstrates how a particular type of mutation in this mice was the cause of failure of previous gene therapy attempts.

Legally Blind Mom Sees New Baby With Special Eyewear

A specialized piece of eyewear gave a legally blind woman from Ontario, Canada, the opportunity to do something that new parents may take granted — see her baby hours after his birth.

Students build sonar based watch for helping the blind to navigate

When a biologist who studies bats and a computer scientist cross paths, amazingly cool things can happen. Cool things such as a sonar device to assist the visually impaired.

Does a full vision restoration happen after treatment from being blind from birth?

A partial restoration of sight is possible in individuals blind from birth, thanks to the most recent advances in research. However, a group of researchers of the Mind/Brain Center of the University of Trento and of the University of Montréal in Canada have discovered that the functional reorganization of the brain happens in individuals who, for a long period, experienced a long sense deprivation, which could potentially impede complete sight restoration.

Is a whole eye transplant possible?

When we talk about an eye transplant, we usually refer to a cornea transplant, in the present day scenario. No one so far has been able to remove a complete eye from a donor, and transplant it into a recipient and make the eye function. But it looks like this is about to change...

Japanese woman is first recipient of next-generation iPS stem cells for macular degeneration

A Japanese woman in her 70s has become the first person in the world to receive retinal cells derived from induced pluripotent stem cells (iPS). In a two-hour procedure on September 12, 2014, a team of three eye specialists lead by Dr Yasuo Kurimoto of the Kobe City Medical Center General Hospital, Japan, implanted a 1.3 by 3.0 millimetre sheet made of retinal pigment epithelium (RPE) cells into one eye of this patient, who was diagnosed with age-related macular degeneration (AMD).

A detailed molecular map for eye disease

Understanding eye diseases is tricky enough. Knowing what causes them at the molecular level is even more confounding.

To understand eye diseases better, University of Iowa (UI) researchers have created the most detailed map to date of a region of the human eye long associated with blinding diseases, such as age-related macular degeneration. The high-resolution molecular map catalogs thousands of proteins in the choroid, which supplies blood and oxygen to the outer retina, itself critical in vision. By seeing differences in the abundance of proteins in different areas of the choroid, the researchers can begin to figure out which proteins may be the critical actors in vision loss and eye disease.

Is Valproic Acid effective in treating patients with Retinitis Pigmentosa?

There have been some reports in academic journals about the use of Valproic acid (VPA) in Retinitis Pigmentosa (RP). We thought we can review the current status of these trials and evaluate where we stand in the outcomes.

Blind veteran shows how he sees world through photography

By the time an inherited eye disease crossed into legal blindness in 2009, Ed Waldrop had already lost the ability to drive and he feared countless other freedoms would soon be next. But what he lost in sight, he gained in a seize-the-day attitude that revived a long-buried, if now unlikely, ambition to make visual art.

(c) JON-MICHAEL SULLIVAN

In the past three years, the Au­gusta Air Force veteran, who serves as the health chaplain at the Charlie Norwood VA Medical Center, has used what free time he has to transform nature, architecture and vintage cars into unique compositions consistent with how he sees the world.


To read more, read the article in The Augusta Chronicle. 

Contact lens allows the blind to 'see'

Engineers in Israel are developing a contact lens they say will allow the blind to recognize
objects by feel rather than sight. The lens is being designed to translate electrical signals into 
shapes on the cornea, producing a tactile effect similar to Braille on the fingertips.





Source

News Bulletin

• Monthly injections may not be necessary for patients with age-related macular degeneration. http://goo.gl/uldMFv

• Converting stem cells to eye tissue could restore sight. http://goo.gl/pJeuiv

• Post-operative healing aided by new gel-based eye fluid. http://goo.gl/YA1B04

• Reversible glue bandage could save injured soldiers' vision. http://goo.gl/fwD2e0

New technique to determine gene carriers for autosomal recessive retinitis pigmentosa

Scientists from Bascom Palmer Eye Institute and Duke University Medical Center have developed a non-invasive technique to determine if individuals carry a gene for the autosomal recessive type of retinitis pigmentosa. 

The work was being presented at the 2014 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Orlando, Florida.

The technique involves collecting a patient's urine and measuring the ratio between specific compounds. The non-invasive process makes subsequent testing clinic-friendly, especially for children being screened.

In search of quantitative biomarkers for the disease, the authors checked on the urinary and plasma dolichol profiles in autosomal recessive RP (arRP) patients and carriers with mutations in the DHDDS gene encoding dehydrodolichol diphosphate synthase, a key enzyme in dolichol biosynthesis. Dolichols are long chain polyisoprenoid alcohols composed of 17-21 isoprene units.

Mutations in the DHDDS gene lead to a characteristic shortening of plasma and urinary dolichols, which, as per the authors of this study, can be used as a functional readout of the enzyme. Urinary and plasma D18/D19 ratios reliably determine if a DHDDS genotype is disease-causing. 

D18/D19 ratio is a viable objective functional biomarker and can be readily adapted as a clinical test for arRP diagnosis and carrier screening with DHDDS or other genetic mutations that impair dolichol biosynthesis.

Source

DENAQ, a new chemical that may restore sight in retinitis pigmentosa and macular degeneration

Scientists from the University of California, Berkeley report on a chemical ‘photoswitch’ named DENAQ that may be a potential drug for treating patients suffering from blinding diseases such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD).

RP and AMD are blinding diseases caused by the degeneration of rods and cones, leaving the remainder of the visual system unable to respond to light. In the paper published in Neuron, the authors led by Dr Richard H Kramer report about a chemical photoswitch named DENAQ that restores retinal responses to white light of intensity similar to ordinary daylight, compared to earlier attempts at photoswitch that required very bright ultraviolet light, making it unsuitable for use in patients. In experiments conducted on three-month to six-month-old healthy mice, and on mice carrying a mutation causing nearly all their rods and cones to degenerate by the time they were a month old, a single intraocular injection of DENAQ has been able to photosensitize the blind retina for about 3 days, restoring electrophysiological and behavioral responses with no toxicity. DENAQ also is able to rapidly turns itself off, allowing rapid repeated stimulation of the retina. The researchers compared the retinae of DENAQ-injected mice to untreated healthy mice and found no signs of toxicity for up to 30 days after the injection.

Retinas with damaged rods and cones are subject to several morphological and biochemical changes, making them different from a healthy retina in more than one way. Experiments on mouse strains with functional, nonfunctional, or degenerated rods and cones show that DENAQ is effective only in retinas with degenerated or dead photoreceptors. Apparently, the degenerated outer retinal cells help in DENAQ photosensitization due to changes in electrophysiological characteristics, while the presence of intact photoreceptors possibly prevent this action. This appears to give it significant advantage, since this selective action on diseased tissue alone may potentially reduce side effects on healthy retina.

DENAQ confers light sensitivity on a hyperpolarization-activated inward current that is enhanced in degenerated retina, enabling optical control of retinal ganglion cell firing. The acceptable light sensitivity, favorable spectral sensitivity, and selective targeting to diseased tissue make DENAQ a prime drug candidate for vision restoration in patients with end-stage RP and AMD.

The researchers plan on conducting more experiments, including in larger animals before its safety can be established and any clinical trials can be considered.

To watch a video of Dr Kramer explaining his work, click here.

Sources: Neuron, Univ of California, Berkeley, Kramer Lab, The Scientist

Editor's note: The drug appears to have an exciting potential to help patients with retinitis pigmentosa and age-related macular degeneration. There are two thoughts though. 

1. Such a drug may only work in advanced stages of the disease, considering we will have to wait for the retinal cells to die before it can act.

2. We also need to know how long the effect of one injection lasts. Such treatment may require repeat injections over a long-term, something similar to Lucentis or Avastin.

Technology to detect early diabetic retinopathy

Yissum Research Development Company, the technology transfer arm of the Hebrew University of Jerusalem, has introduced a method for detecting retinal micro-aneurysms that potentially pose a high risk for leakage of blood and blood products, which can lead to visual impairment in diabetic retinopathy (amongst other retinal vascular diseases). This method is likely to enable early diagnosis and treatment of the condition, potentially minimizing damage and saving vision. 

The technology has been patented by Yissum and is currently searching for an appropriate partner for the further development and commercialization of the invention. 

Dr. Yaakov Nahmias and his team from the Center for Bioengineering at the Hebrew University of Jerusalem developed a computational method to identify microvascular regions with high risk of leakage based on fluid dynamics. The method will enable ophthalmologists to identify microaneurysms with a high risk of leakage using adaptive optics. The scientists found that high risk is correlated with increased level of a protein called Von Willebrand factor (vWF), which has been associated with early development of diabetic retinopathy.

Retinal microaneurysms are dilations of small blood vessels in the retina, and an early feature of diabetic retinopathy, one of the leading causes of blindness worldwide. Retinal microaneurysms reduce vision because they eventually cause fluid leakage from blood vessels and retinal edema. Localized leakage can be detected and treated using laser ablation slowing the progression of diabetic blindness.

Source